Why healthcare stocks got a bump from Trump

Glenn Freeman  |  28/11/2016Text size  Decrease  Increase  |  

Glenn Freeman: I'm Glenn Freeman for Morningstar and I'm joined today by Chris Kallos, our Australian healthcare equities analyst.

Chris, thanks for joining us.

Chris Kallos: Thank you, Glenn.

Freeman: Just firstly Chris, Australian healthcare companies have been performing quite strongly, particularly in recent years. Why is this?

Kallos: Well, a combination of things. Firstly, on a relative basis, we've seen the mining sector fall away. Banks have been up and down.

So, healthcare has been pretty consistent.

Added to that is the fact that many of the large healthcare companies that we have around us today have been around for a number of decades during periods of volatility.

So, what we're seeing now is a seasoned performance, if you will. People have gone through rough patches who have benefited from consolidation, who have worked up very strong business models--and names that come to mind include Ramsay, Sonic, CSL.

They've been around for decades. So, it stands to reason that they've worked out certain wrinkles in their business plans and their business models and that's what we see today.

Freeman: Now, Chris, in the lead up to the U.S. election and in the immediate aftermath, the US healthcare sector has seen some pretty big movement. How has this been reflected in the Australian healthcare sector?

Kallos: Well, the healthcare sector like all the other sectors were bumped on the election of Donald Trump.

There is a high expectation that he will roll back some red tape for drug approvals in the FDA and there's also now a reality of Hillary Clinton not being able to execute or act on her promise to control drug prices.

So, both of those things have been seeing positively for the US healthcare sector and we've moved in tandem out of sympathy or sentiment.

Obviously, not every stock is affected the same way, but companies like CSL, Mayne Pharma on the generics side, theoretically could benefit from this kind of rhetoric on Donald Trump's side.

Freeman: The US government has been conducting an enquiry into generic drug pricing. How has this flowed on to Australian companies?

Kallos: That's right, Glenn. Well, that probe came directly as a result of a few scandals last year in generic pricing and allegations of gouging which fueled a lot of the rhetoric that the democrats were pushing.

The probe itself is into certain generic molecules of doxycycline and digoxin. The only companies that are affected in that space are Mayne Pharma.

However, these are very small components in their overall portfolio. I don't think it's got any bearing on their business as such going forward.

Freeman: Now, just lastly, looking ahead, where do you expect growth will come from for Australian healthcare companies?

Kallos: Given that the large caps, namely, CSL, ResMed, Ramsay and Sonic are all now global companies, I think most of the growth will come offshore. That's definitely the case with Sonic and Ramsay.

Ramsay is the number one private service provider in France, for instance. They've got a very strong business in the UK.

Sonic, likewise, is doing a lot of work in Europe and also the UK. And that makes sense given that their market share is almost kept out in the Australian domestic environment.

 

Video Archive...

Volatility plays to active manager strengths
--  The climate of political volatility in the US holds important implications for investors and the funds they invest in, particularly around Donald Trump's ability to pass legislation through Congress, says Pimco's Libby Cantrill.
Is the FTSE 100 Facing Another Market Crash?
16/06/2017  Ten years on from the pre-crisis FTSE 100 high, Morningstar UK's Emma Wall examines how UK stocks have fared
How to guard against retirement threats
16/06/2017  As retirement approaches, even the best-laid plans can go awry, as Tim Steffen tells Christine Benz, Morningstar US.
PIMCO Global Credit Fund
07/06/2017  The PIMCO Global Credit strategy receives a Morningstar Analyst Rating of Silver due to its sizeable and highly capable credit research team.
PIMCO Income Fund
07/06/2017  Morningstar's Tim Wong looks at the strengths and competitive advantages of this Silver-rated strategy.
3 pockets of opportunity in fixed income
07/06/2017  The head of PIMCO Australia portfolio management explains his views on active management in fixed income and outlines where he sees most value in this space.
Trump administration biggest macro threat for investors
05/06/2017  Even as European political volatility subsides, the US Government remains a considerable threat to financial markets, says Colleen Barbeau, director of equity portfolio management, Franklin Templeton.
Antipodes Global Fund: Class P
01/06/2017  Antipodes constructs this portfolio based on three major objectives--capital preservation, inclusion of attractively priced businesses, and investment resilience.
Investors Mutual WS Future Leaders Fund
01/06/2017  Investors Mutual Future Leaders is a capable strategy focused on investing in Australian companies outside the top 50.
Why the time is right to invest in India
25/05/2017  Indian stocks rallied after the appointment of Narendra Modi as Prime Minister--but then subsequently fell. UK-based investment manager Jonathan Schiessl says now is the time to buy.
When should you pay active fund fees?
23/05/2017  When is it worth paying higher fund fees for active fund management? The single most important factor effecting a fund's relative performance is its price.
Budget 2017: bank levy a potential 4pc hit to big five profits, dividends
10/05/2017  If unable to pass on costs associated with the new levy proposed in the Budget, bank profits and dividends could dive 4 to 5 per cent, in a significant hit to shareholders and customers.
Why PIMCO Australian Bond is a Gold-rated strategy
10/05/2017  Tim Wong explains why PIMCO Australian Bond is Morningstar's most highly rated fixed-interest strategy in this market.
2 leisure stocks weather Cyclone Debbie, Dreamworld fallout
02/05/2017  These two companies with large theme park operations have faced significant challenges in recent times. Morningstar senior equity analyst Brian Han explains how they've fared.
Schroders stays hot on commodities, cooler on tech and defensives
01/05/2017  Long-term investors in Australian shares will continue to find value, but the time for risk-taking on more speculative plays has passed, says Martin Conlon, Schroders’ head of Australian equities
Introducing star ratings to Morningstar Australasia equity research
27/04/2017  What investors can expect from Morningstar's roll-out of its star rating methodology across Australian and New Zealand stocks, as explained by the regional director of equity research, Adam Fleck.
French elections: Macron versus Le Pen
26/04/2017  Following the first round of the French Presidential elections, the 7 May vote is now between Emmanuel Macron and Marine Le Pen. What does it mean for investors?
How climate change will impact your portfolio
20/04/2017  Ignore climate change at your portfolio's peril, says Jeremy Grantham, founder of asset manager GMO.
How dwindling resources will push up commodity prices
13/04/2017  Jeremy Grantham, renowned investor and founder of GMO, explains how a growing population is putting a strain on global resources.
How retirement spending affects withdrawal rates
10/04/2017  Data shows that the withdrawal rate gets higher as spending decreases in retirement, says Michael Kitces, a US-based financial planning expert.